Ogiso, Taro published the artcilePharmacokinetics of ozagrel and its metabolites after intravenous and oral administrations, Application In Synthesis of 94084-75-0, the main research area is ozagrel metabolism pharmacokinetics liver intestine.
The pharmacokinetics of ozagrel, a selective thromboxane A2 synthetase inhibitor, and its metabolites M1 [p-(1H-imidazol-1-ylmethyl)benzoic acid] and M2 [3-[p-(1H-imidazol-1-ylmethyl)phenyl]-2-propionic acid] were investigated in rats. The plasma concentration-time profile of ozagrel was biexponential, with a rapid terminal decay (t1/2b = 0.173 and 0.160 h after doses of 15 and 45 mg/kg, resp.). Metabolites M1 and M2 appeared in plasma immediately after i.v. administration of the parent drug. Similar patterns of metabolites were observed in plasma after oral administration, although concentrations of M2 were higher than those of M1, indicating the metabolic conversion of ozagrel to M2 and M1. However, a saturable 1st-pass clearance was seen after a high oral dose (60 mg/kg) of ozagrel. When M2 was administered i.v., M1 appeared in the circulation at appreciable levels, providing evidence of metabolic conversion of M2 to M1 in the systemic circulation. Ozagrel was partly metabolized to M2 and M1 in rat intestinal mucosa, although the main metabolic site might be in the liver. The results indicate that the metabolic pathway of ozagrel in rats is the conversion of the parent drug to M2 and M1 and the conversion of M2 to M1.
Journal of Pharmaceutical Sciences published new progress about Intestine. 94084-75-0 belongs to class imidazoles-derivatives, name is 4-((1H-Imidazol-1-yl)methyl)benzoic acid, and the molecular formula is C11H10N2O2, Application In Synthesis of 94084-75-0.
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem